Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

45
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
45
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

81
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
81
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

43
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
43
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

36
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
36
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

51
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
51

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of Tacrolimus-induced thrombotic microangiopathy in a heart transplant recipient: Utilizing novel immunosuppression strategies.

JHLT open·2026
Same author

Belatacept as an Emerging Option in Immunosuppression-Induced Thrombotic Microangiopathy After Heart Transplantation.

JACC. Case reports·2026
Same author

Biomarkers and genetic determinants of cardiac sarcoidosis: current status, the unmet needs and future perspectives.

Frontiers in cardiovascular medicine·2026
Same author

Net Prolongation of Life in Advanced Heart Failure: An Intentional Strategy of Durable LVAD Therapy Followed by Heart Transplantation.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2026
Same author

Mechanical circulatory support for cardiogenic shock in takotsubo syndrome.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Vericiguat Therapy Is Associated with Reverse Myocardial Remodeling in Chronic Heart Failure with Reduced Ejection Fraction.

Journal of cardiovascular development and disease·2026

Related Experiment Video

Updated: Sep 27, 2025

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.1K

Cell Therapy in Heart Failure with Preserved Ejection Fraction.

Sabina Frljak1, Gregor Poglajen1, Bojan Vrtovec1

  • 1Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Slovenia.

Cardiac Failure Review
|April 11, 2022
PubMed
Summary

Heart failure with preserved ejection fraction (HFpEF) treatment may be improved by CD34+ cell therapy. Increasing CD34+ cells in the heart could enhance microvascular function and diastolic parameters in HFpEF patients.

Keywords:
CD34+Heart failurecell therapyheart failure with preserved ejection fraction

More Related Videos

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model
07:03

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model

Published on: March 18, 2019

7.3K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.0K

Related Experiment Videos

Last Updated: Sep 27, 2025

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

12.1K
Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model
07:03

Implantation of hiPSC-derived Cardiac-muscle Patches after Myocardial Injury in a Guinea Pig Model

Published on: March 18, 2019

7.3K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.0K

Area of Science:

  • Cardiology
  • Regenerative Medicine

Background:

  • Heart failure with preserved ejection fraction (HFpEF) is a leading cause of heart failure hospitalizations with limited treatment options.
  • Emerging evidence links HFpEF to systemic inflammation, microvascular endothelial dysfunction, and rarefaction.
  • CD34+ cells are crucial for neovascularization and pro-angiogenic cytokine production in ischemic tissues.

Purpose of the Study:

  • To investigate the potential of CD34+ cell therapy as a novel treatment for HFpEF.
  • To explore the correlation between CD34+ cell numbers and diastolic function in HFpEF patients.

Main Methods:

  • Analysis of the relationship between diastolic function and CD34+ cell counts in HFpEF patients.
  • Review of pilot clinical data on the effects of CD34+ cell therapy in HFpEF.

Main Results:

  • Decreased CD34+ cell numbers correlate with worsening diastolic function in HFpEF.
  • Pilot data suggest CD34+ cell therapy may improve diastolic function and functional capacity in HFpEF.

Conclusions:

  • Increasing myocardial CD34+ cells is a plausible therapeutic strategy for HFpEF.
  • CD34+ cell therapy shows promise as a novel treatment for heart failure with preserved ejection fraction.